IP Library Granted Patent US 11,827,720
Granted Patent B2
US 11,827,720 · App. 15/677,667 · Granted Nov 28, 2023

Multivalent immunoglobulins

Inventors: Florian Ruker (Vienna, AT); Gottfried Himmler (Gross-Enzersdorf, AT); Gordana Wozniak-Knopp (Vienna, AT)
Assignee: F-star Therapeutics Limited
C07K16/468C07K16/005C07K16/28C07K16/2887C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,827,720
App. No.
15/677,667
Granted
Nov 28, 2023
Kind
B2
Abstract

The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.

Claims (9)

1. A polypeptide comprising a scaffold comprising an immunoglobulin fold comprising a human IgG1 antibody CH3 constant domain, wherein

(i) said antibody CH3 constant domain comprises at least six structural loops, said antibody CH3 constant domain comprising one structural loop region comprising up to 5 amino acid residue changes relative to the amino acid residues of the corresponding wild type IgG1 antibody CH3 constant domain, wherein said one structural loop region is selected from the group consisting of the A-B loop region and the E-F loop region; and

(ii) said antibody CH3 domain comprises a solvent accessible surface comprising at least three of said residue changes at positions 17-19, or at positions 71-73 and 76-77 of SEQ ID NO: 21 or at least four of said residue changes at positions 71-73 and 76-77 of SEQ ID NO: 21;

wherein said immunoglobulin fold comprises said loop regions defined in part (i) and (ii),

wherein said up to 5 amino acid residue changes in said one structural loop region does not encompass incorporation of a peptide of predetermined amino acid sequence that binds an epitope independently of its insertion into said one structural loop region.

2. The polypeptide of claim 1 , wherein at least two solvent accessible surfaces comprise said residue changes.

3. The polypeptide of claim 1 , wherein said residue changes of (i) is a combination of an insertion and at least one substitution.

4. The polypeptide of claim 1 , wherein said polypeptide comprises an antibody comprising an Fc domain, wherein said Fc domain comprises said scaffold.

5. A kit comprising the polypeptide of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: F-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTWICKLUNGSGES. M.B.H
To: F-STAR THERAPEUTICS LIMITED
Reel/Frame 057557/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2018
From: HIMMLER, GOTTRIED; RUKER, FLORIAN; WOZNIAK-KNOPP, GORDANA
To: F-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTWICKLUNGSGES.M.B.H.
Reel/Frame 047232/0276 →
Priority Claims (1)
AT A 1147/2006 · Jul 5, 2006 · national
Continuity (2)
Continuation 12307578
Related Publication 20180051095A1 · Feb 22, 2018